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Abstract
The anticlotting and antithrombotic activities of heparin, heparan
sulfate, low molecular weight heparins, heparin and heparin-like
compounds from various sources used in clinical practice or under
development are briefly reviewed. Heparin isolated from shrimp
mimics the pharmacological activities of low molecular weight hepa-
rins. A heparan sulfate from Artemia franciscana and a dermatan
sulfate from tuna fish show a potent heparin cofactor II activity. A
heparan sulfate derived from bovine pancreas has a potent antithrom-
botic activity in an arterial and venous thrombosis model with a
negligible activity upon the serine proteases of the coagulation cas-
cade. It is suggested that the antithrombotic activity of heparin and
other antithrombotic agents is due at least in part to their action on
endothelial cells stimulating the synthesis of an antithrombotic hepa-
ran sulfate.
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Sites of action of antithrombotic
drugs
The leading causes of death in the United
States are diseases that involve heart and
blood vessels, and as a consequence throm-
bosis (1). The incidence of death due to this
cause is almost two times higher than the
second, namely, cancer (Figure 1). This rate
explains the current efforts to develop spe-
cific and potent antithrombotic agents.
The possible sites of action for antithrom-
botic compounds include blood itself, com-
posed of plasma proteins and lipids, and
cells. The red cells seem not to be a target for
antithrombotic drugs, whereas white cells
and platelets are intimately involved in throm-
bus formation.
The protease network in coagulation, fi-
brinolysis and the kallikrein-kinin system is
shown in Figure 2. This cascade of events
consists of a series of steps for the activation
of serine proteases and modulation by spe-
cific inhibitors called serpins. The ultimate
700
Braz J Med Biol Res 34(6) 2001
H.B. Nader et al.
goal of the coagulation system is the forma-
tion of clot that is the result of the limited
proteolysis of a soluble protein from plasma
(fibrinogen) into an insoluble protein (fi-
brin).
Heparin: structure and mechanism
of action
Heparin was the first compound used as
an anticoagulant and antithrombotic agent.
Heparin was isolated by McLean in Canada
in 1916 from a preparation of dog liver. The
commercial heparin preparations, introduced
in clinical practice 60 years ago, are from
hog and bovine intestinal mucosa, as well as
bovine lung. Chemical and enzymatic analy-
ses and NMR spectroscopy revealed the main
structural features of heparin. In our labora-
tory we have shown that heparin is mainly
composed of a hexasaccharide containing
iduronic acid 2-O-sulfate, glucosamine 2-6-
disulfate and non-sulfated glucuronic acid
(2). This sequence is the main unit in the
heparin molecule (Figure 3). Small varia-
tions occur among heparins from different
sources.
Heparin acts as anticoagulant compound
because it forms a ternary complex with
antithrombin III and the different serine pro-
teases of the coagulation cascade. The inhi-
bition of thrombin by antithrombin is accel-
erated by more than 1,000 times in the pres-
ence of heparin. Heparin is also capable of
potentiating the effect of another serpin called
heparin cofactor II that is specific for throm-
bin. It also releases and increases the synthe-
sis of the tissue factor pathway inhibitor by
endothelial cells.
Some difficulties and side effects have
been observed with the continuous clinical
use of heparin, such as frequent activated
partial thromboplastin time monitoring, vari-
able anticoagulant effects, the inability to
inhibit thrombin bound to the clot, and the
occurrence of thrombocytopenia in some
patients.
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Figure 1. Causes of death in the US. Data from the American Heart Association (1993).
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Antithrombotic activity of heparin
fractions and heparin fragments
prepared by chemical and enzymatic
depolymerization
By electrofocusing (3-5) it was possible
to show that commercial heparin prepara-
tions are composed of molecules with differ-
ent molecular masses ranging from 3 to 30
kDa (Figure 4). These different fractions
were prepared on a large scale and those
with high molecular mass were found to
exhibit a potent anticoagulant effect in vitro,
with values ranging from 200 to 300 IU/mg,
whereas molecules of 3 kDa or less showed
a negligible anticoagulant effect (around 10
IU/mg). In contrast, when these molecules
were assayed in an in vivo model of throm-
bosis, both the high and low molecular weight
(LMW) fractions were found to be potent
antithrombotic drugs (Figure 4). Results of
the in vivo model of thrombosis also showed
that the different heparin preparations con-
tain different proportions of high and LMW
Figure 3. Methods of preparing low molecular weight heparins. Molecular sieving, gel filtration on Sephadex G-50 (29); nitrous acid, limited nitrous
acid reaction (30); esterification and ß-elimination, benzylation and ß-elimination by a method developed by Aventis; heparinase, limited degradation
with heparinase from Flavobacterium heparinum (2); Fenton reaction, oxidation with free radicals generated from H2O2 and Cu2+ (3).
components, and this could account for the
differences in clinical results.
Since the content of LMW heparins pre-
sent in the heparin preparations with high in
vivo antithrombotic activity accounts for only
5% of the commercial heparins, we decided to
depolymerize heparin. Depolymerization was
obtained by the Fenton reaction (3) that cleaves
the heparin molecule in the glucuronic acid
moieties, as well as by degradation with
heparitinase II (6). Using these methods it was
possible to produce LMW heparins in high
yields, as shown by the electrofocusing profile
of both standard and LMW heparin (Figure 5).
When these LMW heparin fractions were tested
in venous thrombosis models in vivo, namely,
ligature of the vena cava, injection of kaolin
into the mesenteric vein and injection of col-
lagen into the femoral vein (6), they exhibited
a more potent effect than standard heparin
(Figure 6). Table 1 shows that the LMW hepa-
rins have a low anticoagulant effect in a whole
plasma assay used to measure thrombin inhi-
bition. Nevertheless, they exhibit potent anti-
Molecular sieving Nitrous acid Esterification
ß-Elimination
Heparinase Fenton reaction
(free radicals)
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Figure 4. Anticoagulant and anti-
thrombotic activities of heparin
fractions obtained by electrofo-
cusing. A, Toluidine blue stain-
ing. B, Precipitated complexes
of ampholine-heparin fractions
photographed against a black
background. Lanes 1 to 5, Phar-
maceutical companies (1: Riker;
2: Roche; 3: Wilson; 4: Lederle;
5, Upjohn). USP, United States
Pharmacopea anticoagulant as-
say; MM, molecular mass.
factor Xa activity, and also a dramatic effect
on thrombus formation in vivo. Both standard
heparin and LMW heparin bind to antithrom-
bin, which has a binding site for thrombin and
another for factor Xa. While standard heparin
can modulate both sites, LMW heparin can
interact only with the site for factor Xa, which
explains its low anticoagulant activity and
high anti-Xa activity in vitro.
These pioneering results led the pharma-
ceutical industries to search for different
methods of heparin depolymerization in the
eighties. Figure 3 shows the different com-
mercially available heparins and the differ-
ent methods for their preparation, namely,
Fenton reaction (ardeparin and parnaparin),
nitrous acid degradation (nadroparin and
dalteparin), esterification and ß-elimination
(enoxaparin), heparinase (tinzaparin), and
molecular sieving. The method of prepara-
tion produces structural differences between
the commercial LMW heparins (7,8) and, as
a consequence, the Food and Drug Adminis-
tration considers them different drugs. Three
different LMW heparins are already com-
mercialized in Brazil, e.g., enoxaparin
(clexane), dalteparin (fragmin) and nadrop-
arin (fraxiparina). In the last decade there
was a tremendous increase in the sales of
LMW heparins, reaching 2.5 billion dollars
in 1999 compared to 150 million dollars of
standard heparins. Examples of the use of
LMW heparins have been reviewed (9-14).
Antithrombotic activity of other
heparin-like compounds
Several other related compounds are be-
ing tested as antithrombotic agents. For in-
stance, last year we isolated in high yields
and characterized a heparin from the head of
the Penaeus shrimp (15). So far, these tis-
sues are of no commercial value since they
are discards of the shrimp industry. When
3.0
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compared to standard heparin, this heparin
shows a lower inhibition of thrombin and a
similar effect on factor Xa (Figure 7A). The
shrimp heparin also has a strong inhibitory
effect on heparin cofactor II and a potent in
vivo antithrombotic activity in rabbits (Table
2). Thus, the pharmacological profile of this
heparin resembles that of the LMW hep-
arins. The commercial appeal of this heparin
is great, since in Europe heparin of bovine
origin has been prohibited because of prion
disease. Thus, at present the only commer-
cial source is hog mucosa. Furthermore, this
heparin, without any chemical depolymer-
ization introducing new elements in its mol-
ecule, is perhaps a safer drug when com-
pared to the other LMW heparins. This hep-
arin is now being prepared in large amounts
for experiments on monkeys and man.
Another interesting compound is the hep-
aran sulfate from bovine pancreas. This com-
pound is a better antithrombotic agent in a
rat model of venous thrombosis (16) than
standard and LMW heparins (Figure 6).
Chondroitin sulfate from cartilage and der-
matan sulfate from pig skin show no effect.
When tested in a guinea pig arterial throm-
bosis model (17), pancreatic heparan sulfate
also showed a potent inhibitory effect com-
parable to heparin (Figure 8). It should be
mentioned that the type of thrombus is dif-
ferent in arterial and venous vessels. The
arterial thrombus is mainly due to the aggre-
gation of platelets, whereas the venous throm-
bus is related to fibrin deposition. This hep-
aran sulfate has no effect on AT-III-medi-
ated inhibition of serine proteases. Curiously,
a heparan sulfate prepared from bovine lung
has low antithrombotic activity.
Heparan sulfate from bovine pancreas
has little effect on heparin cofactor II. On the
other hand, heparan sulfate from the crusta-
cean Artemia franciscana is a potent modu-
lator of heparin cofactor II (18), as also are
dermatan sulfate from bovine pancreas and
heparin (Figure 7B).
Another dermatan sulfate extracted from
Figure 5. Electrofocusing of hep-
arin and low molecular weight
(LMW) heparin prepared by the
Fenton reaction. The molecular
masses (MM) of standards are
given in kDa on the right side of
the figure.
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Figure 6. In vivo antithrombotic
activities of heparin, low molec-
ular weight (LMW) heparins,
heparan sulfate and other gly-
cosaminoglycans in different
venous models. APTT, activated
partial thromboplastin time.
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Table 1. In vitro anticoagulant activities and in vivo antithrombotic activities of heparins and low molecular
weight (LMW) heparins.
Sample MM (kDa) In vitro (U/mg) In vivo
antithrombotic
USP APTT Anti-Xa activity
Chr. Y.W.
Heparin
Intestine 15.1 140 135 106 69 176
Lung 9.6 130 74 90 60 96
Pancreas 9.6 140 154 129 68 84
LMW heparin
Oxidation 4.5 48 37 87 162 119
Molecular sieving 4.6 49 31 100 187 161
Heparinase 5.8 45 22 78 265 146
APTT, activated partial thromboplastin time; Chr., chromogenic assay; Y.W., Yin and Wessler assay; USP,
United States Pharmacopea anticoagulant assay; MM, molecular mass.
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Figure 7. In vitro anticoagulant activities of different heparinoids. A, AXa and AIIa activity of shrimp heparin
compared to bovine heparin from Ref. 15. B, Heparin cofactor II activity of Artemia franciscana from Ref. 18. C,
Heparin cofactor II activity of dermatan sulfate from tuna fish. DS, dermatan sulfate; HS, heparan sulfate.
Table 2. Effect of low molecular weight (LWM) and shrimp heparins on the induction of thrombosis by laser
shots.
Agent Dosage (mg/kg) Injection route Number of laser shots*
5 min 15 min
Saline Exp. 1 - sc 2 3
Saline Exp. 2 - sc 3 3
LMW heparin 1.0 sc 7 5
LMW heparin 2.5 sc 5 3
Shrimp heparin Exp. 1 1.0 sc 5 6
Shrimp heparin Exp. 2 1.0 sc 7 7
LMW heparin 0.5 iv 10 7
Shrimp heparin Exp. 1 0.25 iv 6 5
Shrimp heparin Exp. 2 0.25 iv 5 4
Shrimp heparin Exp. 1 0.5 iv 6 6
Shrimp heparin Exp. 2 0.5 iv 6 5
*Number of laser shots needed to produce a thrombus in rabbit peritoneum 5 or 15 min after injection.
sc, subcutaneous; iv, intravenous; Exp., experiment.
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Figure 8. In vivo antithrombotic
activity of glycosaminoglycans in
an arterial model. Data are from
Ref. 17. Note: as authors of this
paper we have the right to repro-
duce our previous data in re-
views.
Table 3. Antithrombotic sulfated compounds (ap-
proved or under development).
Heparin derivatives
Heparin
LMW heparins
Synthetic heparin pentasaccharide (ultra LMW
heparins)
Semisynthetic heparin derivatives
Non-heparin glycosaminoglycans
Dermatan sulfates
Heparan sulfates
Chondroitin sulfates
Heparinoids
Sulfated compounds
Lactobionic acid
Compound Y
Fucans
LMW, low molecular weight.
tuna fish skin (also a discard from the food
industry) has a potent activity on heparin
cofactor II-mediated thrombin inhibition
(Figure 7C).
Table 3 summarizes some of the com-
pounds approved or under development as
antithrombotic drugs. LMW heparins are
widely used and the pharmaceutical industry
is now testing a synthetic heparin pentasac-
charide in humans. Non-heparin glycosami-
noglycans such as heparan and dermatan
sulfate are already in clinical trials; highly
sulfated chondroitin sulfates have been pro-
duced and used topically. Sulfated com-
pounds, such as lactobionic acids, pentosan
sulfate and compound Y (19,20) also show
antithrombotic activities. Another possible
commercial source for antithrombotic com-
pounds is brown seaweed (algae) that con-
tains special sulfated polysaccharides named
fucans (21).
Vascular endothelial cell response to
antithrombotic agents
We have discussed so far the site of
action of these drugs in the protease network
of coagulation. As previously mentioned,
the vessel wall is another site of action for
antithrombotic compounds. In the eighties
Colburn and Buonassisi (22) reported that
an endothelial cell line in culture showed
blood compatibility, i.e., the surface of these
cells had antithrombotic activity. Thus, when
the surface of endothelial cells changes, there
is a chance of thrombus formation. Among
the compounds present on the cell surface
Dermatan sulfate
N-Acetylated heparan sulfate
Heparan sulfate (lung)
Heparan sulfate (pancreas)
Heparin
Control
0 40 60 80 10020
% of animals with thrombus
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Figure 9. Stimulation of heparan
sulfate synthesis in endothelial
cells by different antithrombotic
agents. GAGPS and MPS: mix-
ture of glycosaminoglycans
from Organon; Op 386, CY 222,
CY 216, LW 10082, and LW
10282: low molecular weight
(LMW) heparins from different
pharmaceutical industries; sule-
paroid: oversulfated chondroitin
sulfate; compound Y: cyclic
octaphenol-octasulfonic acid;
tetra-4S, -5S, and -6S: tetra-,
penta- and hexasulfated tetra-
saccharides obtained from hep-
arin by heparinase degradation
(26).
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and in the extracellular matrix of endothelial
cells are heparan sulfate proteoglycans. These
heparan sulfates have been shown to possess
antithrombotic activity in different models
(22). This activity was absent in the heparan
sulfate from smooth muscle cells (22).
When heparin is given to a patient, the
endothelium is possibly one of the sites of
action for the compound. Endothelial cells
(rabbit aorta (23) and human umbilical cord
(24)) exposed to heparin increase the syn-
thesis of the antithrombotic heparan sulfate
present on the cell surface, as well as the one
released into the medium (25-27). As shown
in Figure 9, this effect is also elicited by
LMW heparins (26). When heparin was frag-
mented with heparinase from Flavobacte-
rium heparinum (28) and the different frag-
ments were also tested as elicitors of the
synthesis of endothelial heparan sulfate (26),
it was shown that the minimum structural
requirement needed to enhance the synthesis
of antithrombotic heparan sulfate is the pres-
ence of a pentasulfated tetrasaccharide (Fig-
ure 9). N-Desulfation of heparin completely
abolishes the stimulating activity. Other sul-
fated compounds, such as lactobionic acids,
that consist of two sulfated lactose residues
linked by a sequence of 3 to 12 carbons, a
cyclic octaphenol-octasulfonic acid (com-
pound Y), dextran sulfate, oversulfated chon-
droitin sulfates, a fucan from brown sea-
weed (21) and other compounds that possess
antithrombotic activity also increase the syn-
thesis of the endothelial antithrombotic hep-
aran sulfate (Figure 9).
Since an increased synthesis of heparan
sulfate chains is observed when the cells are
exposed to heparin and other antithrombotic
agents, the hypothesis has been raised that
the in vivo antithrombotic activity of these
compounds is related, at least in part, to the
increased production of this peculiar hepa-
ran sulfate by endothelial cells. In favor of
this hypothesis are the findings that heparin-
tetrasaccharide and compound Y, which are
antithrombotic agents in vivo, exhibit a neg-
ligible activity in vitro on the serine pro-
teases of the coagulation cascade.
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